Sign in
CompletedNo phase

Liposomal vs Conventional Oral Iron After Sleeve Gastrectomy

Key facts

Who runs it
Medeni Şermet
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
70 people enrolled
Started
1 Sept 2025
Ended
31 Jul 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Liposomal Iron
  • conventional oral iron
Record updated
3 November 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Age between 18 and 65 years
  • History of laparoscopic sleeve gastrectomy performed at least 6 months prior to enrollment
  • Diagnosis of iron deficiency anemia, defined as:
  • Hemoglobin <12 g/dL in women or <13 g/dL in men, and
  • Serum ferritin <30 ng/mL or transferrin saturation (TSAT) <20%
  • Mild to moderate anemia (hemoglobin ≥9 g/dL)
  • Ability to take and swallow oral medications
  • Willingness to participate and provide written informed consent Exclusion Criteria
  • Active gastrointestinal disease (e.g., inflammatory bowel disease, peptic ulcer disease, or gastrointestinal bleeding)
  • Chronic kidney disease with estimated GFR <30 mL/min/1.73 m²
  • Use of oral or parenteral iron, vitamin B12, or folate supplementation within the previous 3 months
  • Iron overload or hemochromatosis (serum ferritin >300 ng/mL)
  • Known allergy or intolerance to iron preparations
  • Active malignancy
  • Pregnancy or breastfeeding
  • Known hemoglobinopathies (e.g., thalassemia, sickle cell disease)
  • Blood transfusion within the previous 1 month
  • Cognitive or psychiatric disorder interfering with study participation or protocol adherence

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Low-dose liposomal iron (17-34 mg elemental/day) was compared with standard conventional oral iron (100-200mg elemental/day) in the treatment of iron deficiency anemia following sleeve gastrectomy. Liposomal iron provided superior hematological improvement and gastrointestinal tolerance.

The 2 groups in the trial

  • Arm 1 Title: Liposomal Iron (Group LD)Treatment being tested

    Participants with iron deficiency anemia after laparoscopic sleeve gastrectomy receiving oral liposomal iron.

    Treatment: Liposomal Iron

  • Arm 2 Title: Conventional Iron (Group KD)Existing treatment, for comparison

    Participants with iron deficiency anemia after laparoscopic sleeve gastrectomy receiving conventional oral ferrous iron preparations.

    Treatment: conventional oral iron

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Comprehensive Hematological and Biochemical Comparison of Low-Dose Liposomal Iron Versus Standard-Dose Conventional Oral Iron in Iron Deficiency Anemia Following Sleeve Gastrectomy: A Prospective, Randomized Clinical Trial
Record updated
3 November 2026